| Not Yet Recruiting | Using Healthy Gut Bacteria to Boost Immune Treatment for Advanced Bowel Cancer NCT07486492 | The First Affiliated Hospital of Xiamen University | EARLY_Phase 1 |
| Not Yet Recruiting | A Clinical Study of BioTTT001 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Canc NCT06283134 | China Medical University, China | Phase 1 |
| Not Yet Recruiting | Lubiprostone Combined With Maintenance Therapy for Prevention of Postoperative Recurrence in Peritoneal Metast NCT07405736 | Sun Yat-sen University | Phase 2 |
| Recruiting | COLONYVAQ™, a Quantum-Classical Guided Personalized Neoantigen Vaccine for MSS Stage III Colorectal Cancer NCT07328087 | Biogenea Pharmaceuticals Ltd. | EARLY_Phase 1 |
| Recruiting | Dual-Target CAR-NK Cells for Biomarker-Selected Advanced Colorectal Cancer NCT07462650 | Beijing Biotech | Phase 1 / Phase 2 |
| Recruiting | Study of Safety/Feasibility of a Hybrid Model of Tertiary and Community Delivery of Hepatic Artery Infusion Ch NCT07201519 | Michael J Cavnar, MD | Phase 2 |
| Not Yet Recruiting | Continuous or Intermittent Cetuximab Plus FOLFIRI as First-line Treatment in RAS/BRAF Wild-type mCRC Patients NCT07004413 | Charite University, Berlin, Germany | Phase 3 |
| Recruiting | Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Colorectal NCT07193862 | Northwell Health | EARLY_Phase 1 |
| Recruiting | INFINITIVE: ImmuNotherapy For PatIeNts wIth colorecTal LIVer MEtastases NCT07172282 | Northwell Health | EARLY_Phase 1 |
| Recruiting | A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors NCT06889610 | Fudan University | Phase 2 |
| Recruiting | A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC NCT07244705 | Anbogen Therapeutics, Inc. | Phase 1 / Phase 2 |
| Recruiting | STREAM-2: Second-line Treatment With REgorafenib in Advanced RAS-Mutant Colorectal Cancer NCT07213570 | National Cancer Institute, Naples | Phase 2 |
| Recruiting | Colorectal Metastasis to Liver Extraction With Auxiliary Transplant and Delayed Resection NCT06698146 | Northwestern University | — |
| Not Yet Recruiting | An Explorative Study of HRS-2189 Combined With Adebrelimab and BP102 for Metastatic Colorectal Cancer NCT07061210 | Fudan University | Phase 2 |
| Not Yet Recruiting | Efficacy and Safety of DEB-TACE Combined With HAIC Versus HAIC Alone in Patients With Unresectable CRLM NCT07031570 | Peking University Cancer Hospital & Institute | — |
| Not Yet Recruiting | TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer NCT06589830 | Suzhou Teligene Ltd. | Phase 2 |
| Not Yet Recruiting | Therapeutic Study of 177Lu-CTR-FAPI in Advanced Metastatic Digestive Malignancies NCT07014254 | Xijing Hospital | N/A |
| Not Yet Recruiting | Exploring Sintilimab + Bevacizumab + Decitabine for Advanced pMMR/MSS Colorectal Cancer (After 2+ Prior Therap NCT07007767 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 2 |
| Recruiting | A Dose-Expansion Trial of Intravenous HNF4α srRNA for Unresectable or Metastatic Colorectal Cancer NCT07050394 | Shanghai Changzheng Hospital | EARLY_Phase 1 |
| Not Yet Recruiting | The Efficacy and Safety of IBI351, Cetuximab β Combined With FOLFIRI as First-line /IBI351, Cetuximab β as Sec NCT06959589 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 2 |
| Recruiting | ctDNA-Guided Cetuximab or Bevacizumab Plus Trifluridine/Tipiracil in RAS/BRAF Wild-Type mCRC NCT07012954 | Sun Yat-sen University | Phase 1 / Phase 2 |
| Not Yet Recruiting | Sintilimab Plus Bevacizumab and Chemotherapy in MSS/pMMR Colorectal With no Liver Metastasis NCT06973343 | Anhui Provincial Cancer Hospital | Phase 2 |
| Recruiting | Trifluridine/Tipiracil Plus Regorafenib vs Trifluridine/Tipiracil Plus Bevacizumab for Refractory Metastatic C NCT06992648 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 3 |
| Recruiting | ValproIc Acid to Potentiate Anti-EGFR Treatment Efficacy and Prevent/Revert Resistance in Colorectal Cancer NCT06714357 | National Cancer Institute, Naples | Phase 2 |
| Recruiting | Irinotecan Liposomes Combined with Cetuximab + Vermofenib in First-line Failure of Advanced Colorectal Cancer NCT06763029 | Fudan University | Phase 2 |
| Recruiting | Isunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS) NCT06634875 | Buzzard Pharmaceuticals | Phase 2 |
| Recruiting | DEBIRI Plus Chemotherapy vs. Chemotherapy Alone in Colorectal Cancer Liver Metastases NCT06555003 | Tehran University of Medical Sciences | Phase 3 |
| Recruiting | Sequential Immunochemotherapy Treatment with Pembrolizumab Plus Dendritic Cell (DC) Vaccine Followed by Triflu NCT06522919 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Phase 2 |
| Recruiting | ctDNA Monitoring in Patients With HCC and mCRC NCT07001085 | Medical University of Warsaw | N/A |
| Recruiting | Oral Chemotherapy, Targeted Therapy and Immunotherapy With/Without Radiotherapy as 3rd- or Later-line Therapy NCT06764680 | Sun Yat-sen University | Phase 2 |
| Not Yet Recruiting | SHR-1701 Combined with SHR2554 and BP102 for MCRC NCT06679673 | Fudan University | Phase 2 |
| Not Yet Recruiting | A Real-world Study of Chidamide in Combination with PD-1/PD-L1 Antibodies and Anti-angiogenic Agents in Advanc NCT06682247 | Feng Wang | — |
| Recruiting | Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or Ce NCT06540326 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 2 |
| Terminated | First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumo NCT06625515 | Accent Therapeutics | Phase 1 |
| Recruiting | Medical Cannabis in Patients With Advanced Pancreatic and Colorectal Cancer NCT06605430 | HealthPartners Institute | Phase 2 |
| Recruiting | Clinical Study of Irinotecan Liposome (II)-Based Combination Treatment for Irinotecan-resistant Colorectal Can NCT07044921 | Chinese PLA General Hospital | Phase 2 |
| Recruiting | Safety and Efficacy of Fruquintinib Plus Chidamide and Sintilimab in the Third and Later Line Treatment of MSS NCT06685276 | Dai, Guanghai | Phase 2 |
| Recruiting | Technical Feasibility of Modified Early Post-Operative Intraperitoneal Chemotherapy (mEPIC) NCT05913674 | Ciusss de L'Est de l'Île de Montréal | Phase 2 |
| Recruiting | Cetuximab, Irinotecan, Toripalimab in RAS/BRAF Wild-type Ultraselected Right-sided Colorectal Cancer Study NCT06547203 | Sun Yat-sen University | Phase 2 |
| Active Not Recruiting | A Phase 1b Study of WU-NK-101 in Combination With Cetuximab NCT05674526 | Wugen, Inc. | Phase 1 |
| Recruiting | Efficacy and Safety of 90Y Microsphere Combined With FOLFIRI and Bevacizumab in Second-line Treatment of CRLM NCT06447727 | Zhongda Hospital | — |
| Completed | [68Ga]Ga-GZP PET for Early Response Prediction in Colorectal Cancer During Neoadjuvant Therapy NCT06982053 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | N/A |
| Recruiting | Regorafenib and Sintilimab in Combination with Electroacupuncture in MSS CRC NCT06456515 | The First People's Hospital of Changzhou | N/A |
| Recruiting | A Study of NILK-2301 in Patients with Locally Advanced or Metastatic Low Tumor Volume (LTV) Colorectal Cancer NCT06663839 | Light Chain Bioscience - Novimmune SA | Phase 1 |
| Unknown | A Clinical Study of T3011 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer NCT06283303 | China Medical University, China | Phase 1 |
| Recruiting | Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Colorectal Cancer NCT06449989 | Blokhin's Russian Cancer Research Center | — |
| Recruiting | Trifluridine/Tipiracil Combined With Cetuximab in the Treatment of Third-line and Above RAS/BRAF Wild-type mCR NCT06379399 | Wangxia LV | Phase 1 / Phase 2 |
| Recruiting | Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases NCT06300463 | Weill Medical College of Cornell University | Phase 2 |
| Terminated | Holmium-166 TARE in Liver Limited Unresectable Colorectal Cancer Patients NCT06332079 | Gruppo Oncologico del Nord-Ovest | Phase 2 |
| Recruiting | Efficacy and Safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination Wit NCT06282445 | The Fourth Affiliated Hospital of Zhejiang University School of Medicine | Phase 2 |
| Terminated | Evaluation of the Efficacy of Two Guidance Techniques (Standard Injected CT vs Porto-scanner With Angio-CT) fo NCT05665322 | Centre Hospitalier Universitaire de Nīmes | N/A |
| Recruiting | Prospective National Cohort Evaluating Predictive Biomarkers of Resistance to Immunotherapy in Patients With M NCT06353854 | Federation Francophone de Cancerologie Digestive | — |
| Recruiting | Molecular Characterisation of Colorectal Cancer Peritoneal Metastases NCT05513716 | The Christie NHS Foundation Trust | — |
| Not Yet Recruiting | Colorectal Pulmonary Metastases: Pulmonary Metastasectomy Versus Stereotactic Ablative Radiotherapy NCT05808790 | Amsterdam UMC, location VUmc | N/A |
| Recruiting | Exploration of Therapeutic Strategies for NeoRAS Wild-type Metastatic Colorectal Cancer Based on Circulating T NCT06440902 | Fudan University | Phase 2 |
| Recruiting | Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal NCT06008119 | Shanghai Kechow Pharma, Inc. | Phase 3 |
| Recruiting | A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal NCT05759728 | Carina Biotech Limited | Phase 1 / Phase 2 |
| Recruiting | Galunisertib Combined With Capecitabine in Advanced CRC With PM NCT05700656 | The Netherlands Cancer Institute | Phase 1 / Phase 2 |
| Recruiting | XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies. NCT06792435 | Evopoint Biosciences Inc. | Phase 1 / Phase 2 |
| Terminated | Evaluate the Efficacy, Safety and Tolerability of HLX26 and Serplulimab in Patients with MCRC NCT05584137 | Shanghai Henlius Biotech | Phase 2 |
| Terminated | EO4010 in Previously Treated Metastatic Colorectal Carcinoma NCT05589597 | Enterome | Phase 1 / Phase 2 |
| Terminated | Feasibility of 2 Interventions to Reduce Fatigue in Patients With Chemotherapy for Metastatic Colorectal Cance NCT04999306 | Institut du Cancer de Montpellier - Val d'Aurelle | N/A |
| Withdrawn | Neoantigen-Targeted Vaccine Combined With Anti-PD-1 Antibody for Patients With Stage IV MMR-p Colon and Pancre NCT04799431 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 |
| Recruiting | Efficacy of Modified Fruquintinib in Colorectal Cancer Liver Metastases: A Phase II Study NCT06018714 | Sun Yat-sen University | Phase 2 |
| Active Not Recruiting | A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors NCT05736731 | A2 Biotherapeutics Inc. | Phase 1 / Phase 2 |
| Terminated | A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer NCT05678257 | NuCana plc | Phase 2 |
| Completed | TINzaparin Prophylaxis in Patients With Metastatic Colorectal Cancer NCT05625932 | Galician Research Group on Digestive Tumors | Phase 3 |
| Recruiting | In Vivo Lung Perfusion (IVLP) for Colorectal Cancer Metastatic to Lung NCT05611034 | University Health Network, Toronto | Phase 1 |
| Recruiting | Pilot Study for Colorectal Cancer and Advanced Adenoma Detection With the Mainz Biomed Colorectal Cancer Test NCT06864338 | Mainz Biomed | — |
| Recruiting | Early Detection of Treatment Failure in Metastatic Colorectal Cancer Patients NCT05068531 | Centre hospitalier de l'Université de Montréal (CHUM) | — |
| Completed | Phase 2 Study of DKN-01 in Colorectal Cancer NCT05480306 | Leap Therapeutics, Inc. | Phase 2 |
| Recruiting | A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer NCT05200442 | University of Chicago | Phase 1 / Phase 2 |
| Recruiting | FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Witho NCT05727163 | Sun Yat-sen University | Phase 2 |
| Recruiting | Explore Biomarkers Associated With Prognosis of Recurrent and Metastatic CRC After Surgery by Multi-omics Meth NCT05501353 | Second Affiliated Hospital, School of Medicine, Zhejiang University | — |
| Completed | Perioperative Outcomes of Simultaneous Colorectal and Liver Resections NCT05475041 | Fondazione Poliambulanza Istituto Ospedaliero | — |
| Active Not Recruiting | Safety and Activity of PolyPEPI1018 Plus Atezolizumab in Colorectal Cancer. NCT05243862 | Treos Bio Limited | Phase 2 |
| Recruiting | Radioembolization in Elderly/ Fragile Patients With mCRC NCT05092880 | UMC Utrecht | Phase 2 |
| Completed | Dynamics of MSI and Genomic Profile of Colorectal Cancer In the Course of Immune Checkpoint Inhibitor Therapy NCT06414304 | OncoAtlas LLC | — |
| Unknown | Preoperative Systemic Therapy for Colorectal Cancer Peritoneal Metastases NCT05353582 | Sun Yat-sen University | Phase 2 |
| Unknown | Evaluation of Tumour Growth and Oncological Treatment in Patients With CRLM Using Zebra Fish Embryo Model NCT05289076 | University Hospital, Linkoeping | Phase 1 / Phase 2 |
| Active Not Recruiting | Trifluridine/Tipiracil in Combination With Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patien NCT04564898 | Gruppo Oncologico del Nord-Ovest | Phase 1 / Phase 2 |
| Withdrawn | A Phase lb/ll, Open Label, Single Arm Study With Olinvacimab and Capecitabine in mCRC Patients (OLCAP) NCT04751955 | Korean Cancer Study Group | Phase 1 / Phase 2 |
| Active Not Recruiting | Ablation vs Resection of Colorectal Cancer Liver Metastases NCT05129787 | Oslo University Hospital | N/A |
| Completed | Evaluation of Treatment PERSOnalization Based on Its Therapeutic Monitoring in Patients With Metastatic Colore NCT04874207 | Rennes University Hospital | Phase 4 |
| Recruiting | PRELUDE-1 (Prospective Evaluation of Radiotherapy-induced Biologic Effects in Colorectal Cancer Oligometastati NCT04854213 | National Cancer Institute, Naples | N/A |
| Unknown | Radiotherapy Combined With Tislelizumab and Irinotecan in MSS/pMMR Recurrence and Metastatic Colorectal Cancer NCT05160727 | Zhejiang Cancer Hospital | Phase 2 |
| Recruiting | Cryoablation Combined with Sintilimab Plus Regorafenib in Previously Treated Colorectal Cancer Liver Metastasi NCT05057052 | Fudan University | Phase 2 |
| Withdrawn | Local Consolidative Therapy in Colorectal Cancer NCT05062720 | Fox Chase Cancer Center | Phase 2 |
| Active Not Recruiting | Chemoembolization (Lifepearls-Irinotecan) in Patients With Colorectal Cancer and Metastatic Disease NCT04595266 | Grupo Espanol Multidisciplinario del Cancer Digestivo | Phase 2 |
| Active Not Recruiting | Neoadjuvant Safety of Sintilimab + XELOX + Bevacizumab in PMMR/MSS CRLM Patients NCT04940546 | Sun Yat-sen University | Phase 1 / Phase 2 |
| Unknown | A Trial of Camrelizumab Combined With Microwave Ablation and Chemotherapy in the Treatment of Colorectal Cance NCT04888806 | Harbin Medical University | Phase 2 |
| Unknown | The Effect of ePRO on Quality of Life and Prognosis of Patients With Unresectable Metastatic Colorectal Cancer NCT04684095 | Harbin Medical University | N/A |
| Active Not Recruiting | Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI mCRC. NCT04730544 | GERCOR - Multidisciplinary Oncology Cooperative Group | Phase 2 |
| Completed | Severe Neutropenia After HIPEC Using Mitomycin-C NCT05513183 | Gangnam Severance Hospital | — |
| Active Not Recruiting | Registry Platform Colorectal Cancer NCT04867525 | iOMEDICO AG | — |
| Unknown | Chemotherapy and Immunotherapy as Treatment for MSS Metastatic Colorectal Cancer With High Immune Infiltrate NCT04262687 | Federation Francophone de Cancerologie Digestive | Phase 2 |
| Completed | Feasibility Study of a 4 Stage Bowel Obstruction Cancer Diet NCT04898842 | Royal Surrey County Hospital NHS Foundation Trust | N/A |
| Terminated | Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer NCT04607668 | G1 Therapeutics, Inc. | Phase 3 |
| Unknown | COLLISION XL: Unresectable Colorectal Liver Metastases (3-5cm): Stereotactic Body Radiotherapy vs. Microwave A NCT04081168 | Amsterdam UMC, location VUmc | N/A |
| Unknown | Effect of Age, Body Mass Index and Tumor Sidedness in Metastatic Colorectal Cancer NCT04543019 | Assiut University | — |
| Completed | Raman Spectroscopy for Liver Tumours Following Liver Surgery NCT05995990 | Nottingham University Hospitals NHS Trust | N/A |
| Completed | TheraSphere® For Treatment of Metastases in Liver NCT04517643 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | N/A |
| Terminated | Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer NCT04108481 | University of Iowa | Phase 1 |
| Recruiting | Gut Microbiome Dynamics in Metastasized or Irresectable Colorectal Cancer NCT03941080 | University Medical Center Groningen | — |
| Unknown | Precision Medicine for Colorectal Cancer Liver Metastasis Guided by Multi-omics Data Under the Umbrella Theory NCT04525807 | Fudan University | — |
| Unknown | A Phase I/II Study With BM7PE Immunotoxin in Colorectal Cancer Patients NCT04550897 | Oslo University Hospital | Phase 1 / Phase 2 |
| Completed | Efficacy of VIC Regimen in BRAF Mutant Metastatic Colorectal Cancer NCT04790448 | Sun Yat-sen University | Phase 1 / Phase 2 |
| Active Not Recruiting | Tocotrienol and Bevacizumab in Metastatic Colorectal Cancer NCT04245865 | Vejle Hospital | Phase 2 |
| Withdrawn | A Pilot Study to Explore the Role of Gut Flora in Colorectal Cancer NCT04148378 | ProgenaBiome | — |
| Withdrawn | LY3200882 and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer (EORTC1615) NCT04031872 | The Netherlands Cancer Institute | Phase 1 / Phase 2 |
| Unknown | FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer NCT04169347 | Criterium, Inc. | Phase 2 |
| Active Not Recruiting | Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid T NCT03983954 | NeoTX Therapeutics Ltd. | Phase 1 |
| Completed | The mCRC Patients With pMMR/MSS or dMMR/MSI-H Status Received Palliative Chemotherapy Efficacy and Survival NCT04482608 | Sun Yat-sen University | — |
| Active Not Recruiting | Plasma 5hmC Signatures as a Marker of Colorectal / Appendiceal Peritoneal Metastasis NCT04157322 | University of Chicago | — |
| Recruiting | Living Donor Liver Transplant for Unresectable Colorectal Liver Metastases NCT05248581 | University of Rochester | — |
| Completed | To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of YYB101 With Irinotecan, Patie NCT04368507 | CellabMED | Phase 1 / Phase 2 |
| Unknown | Regorafenib and PD-1 Antibody in Combination With Radiotherapy for pMMR/MSS Metastatic Colorectal Cancer NCT04030260 | Sun Yat-sen University | Phase 2 |
| Active Not Recruiting | Regorafenib and Pembrolizumab in Treating Participants With Advanced or Metastatic Colorectal Cancer NCT03657641 | University of Southern California | Phase 1 / Phase 2 |
| Withdrawn | Study of Intratumoral Ipilimumab and TLR4 Agonist GLA-SE in Combination With Systemic Nivolumab and Chemothera NCT03982121 | Gustave Roussy, Cancer Campus, Grand Paris | Phase 1 |
| Unknown | Anticancer Vigilance Of Cardiac Events (AVOCETTE) in Metastatic Colorectal Cancer NCT03923036 | University Hospital, Caen | — |
| Completed | NeoRes Study - Preoperative Chemotherapy in Colorectal Peritoneal Disease Prior to Cytoreductive Surgery and H NCT06903039 | Uppsala University | — |
| Withdrawn | Sym004 Versus TAS-102 in Patients With mCRC NCT03717038 | Symphogen A/S | Phase 3 |
| Completed | Nivolumab and Metformin in Patients With Treatment Refractory MSS Colorectal Cancer NCT03800602 | Emory University | Phase 2 |
| Unknown | Improving Outcome of Selected Patients With Non-resectable Hepatic Metastases From Colo-rectal Cancer With Liv NCT03803436 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Phase 2 |
| Unknown | Irinotecan Drug-eluting Bead Liver Embolisation Registry NCT03697044 | The Christie NHS Foundation Trust | — |
| Completed | A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors NCT03775850 | Evelo Biosciences, Inc. | Phase 1 |
| Terminated | Sym004 Versus Futuximab or Modotuximab in Patients With mCRC NCT03549338 | Symphogen A/S | Phase 2 |
| Unknown | Second-line FOLFIRI + Panitumumab in Subjects With Wild Type RAS Metastatic Colorectal NCT03751176 | Grupo Espanol Multidisciplinario del Cancer Digestivo | Phase 2 |
| Unknown | Quality of Life After Cytoreductive Surgery and Intraperitoneal Chemotherapy NCT03503071 | Kyungpook National University Hospital | — |
| Terminated | QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine NCT03563157 | ImmunityBio, Inc. | Phase 1 / Phase 2 |
| Completed | Modulation Of The Tumour Microenvironment Using Either Vascular Disrupting Agents or STAT3 Inhibition in Order NCT03647839 | Australasian Gastro-Intestinal Trials Group | Phase 2 |
| Withdrawn | Galunisertib and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer NCT03470350 | The Netherlands Cancer Institute | Phase 1 / Phase 2 |
| Completed | Improving SUrgery of Liver Metastases: a Trial of the Arterial Chemotherapy Network NCT03164655 | UNICANCER | Phase 2 |
| Completed | Nab-Sirolimus in Combination With FOLFOX & BEV as 1st Line Therapy in Patients With Advanced or Metastatic Col NCT03439462 | Aadi Bioscience, Inc. | Phase 1 / Phase 2 |
| Completed | A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer NCT03597581 | Inspirna, Inc. | Phase 1 |
| Completed | MGD007 Combined With MGA012 in Relapsed/Refractory Metastatic Colorectal Cancer NCT03531632 | MacroGenics | Phase 1 / Phase 2 |
| Completed | OPTImal PALliative Anti-epidermal Growth Factor Receptor Treatment in Metastatic Colorectal Cancer - NCT03750175 | Karen-Lise Garm Spindler | — |
| Completed | METIMMOX: Colorectal Cancer METastasis - Shaping Anti-tumor IMMunity by OXaliplatin NCT03388190 | University Hospital, Akershus | Phase 2 |
| Recruiting | Living Donor Liver Transplantation With Two Stage Hepatectomy for Patients With Isolated, Irresectable Colorec NCT03488953 | Jena University Hospital | N/A |
| Unknown | Probiotics as Adjuvant Therapy in the Treatment of Metastatic Colorectal Cancer NCT03705442 | Marin Golčić | Phase 2 |
| Completed | A Phase 2 Study of Lamivudine in Patients With p53 Mutant Metastatic Colorectal Cancer NCT03144804 | Massachusetts General Hospital | Phase 2 |
| Completed | FOLFIRI + Panitumumab First-line Treatment in Elderly Patients With Unresectable Metastatic Colorectal Cancer, NCT03142516 | Grupo Espanol Multidisciplinario del Cancer Digestivo | Phase 2 |
| Completed | Predictive Value of Drug Sensitivity Testing Tumorspheres From Patients With Metastatic Colorectal Cancer NCT03251612 | Vejle Hospital | Phase 2 |
| Completed | HepaT1ca: Quantifying Liver Health in Surgical Candidates for Liver Malignancies NCT03213314 | University of Edinburgh | N/A |
| Unknown | The Effects of General Anesthetics on Lymphocytes in Patients Undergoing Colorectal Cancer Resection and Mecha NCT03193710 | Guizhi Du | — |
| Active Not Recruiting | Comprehensive Genomic Profiling of Colorectal Cancer Patients With Isolated Liver Metastases to Understand Res NCT03364621 | University Health Network, Toronto | — |
| Completed | Evaluation of the Safety and the Tolerability of Durvalumab Plus Tremelimumab Combined With FOLFOX in mCRC NCT03202758 | Centre Georges Francois Leclerc | Phase 1 / Phase 2 |
| Completed | Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Pr NCT03007407 | NSABP Foundation Inc | Phase 2 |
| Completed | Study of the Therapeutic Response and Survival of Patients with Metastatic Colorectal Cancer (stage IV) and Tr NCT03133273 | University Hospital, Limoges | N/A |
| Terminated | The p53 Colorectal Cancer Trial NCT03149679 | Haukeland University Hospital | Phase 2 |
| Active Not Recruiting | Assessing How Normal Variations in CT Scanning Affects Its Interpretation NCT03038568 | Memorial Sloan Kettering Cancer Center | — |
| Completed | Ipilimumab, Maraviroc and Nivolumab in Advanced Metastatic Colorectal and Pancreatic Cancer the LUMINESCENCE T NCT04721301 | University Hospital Heidelberg | Phase 1 |
| Unknown | Evaluation of CTCs Combined With Tumor Marker Detection of Efficacy of Chemotherapy in mCRC NCT02948985 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | — |
| Completed | CE-IOUS Impact on Surgical Strategy of Liver Tumours and Liver Metastases NCT05261113 | University of Regensburg | — |
| Completed | AlloStim® Immunotherapy Dosing Alone or in Combination With Cryoablation in Metastatic Colorectal Cancer NCT02380443 | Mirror Biologics, Inc. | Phase 2 |
| Unknown | Panitumumab Skin Toxicity Prevention Trial NCT03167268 | Ospedale San Carlo Borromeo | Phase 2 |
| Unknown | A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy NCT02959151 | Shanghai GeneChem Co., Ltd. | Phase 1 / Phase 2 |
| Completed | Detection of KRAS, NRAS et BRAF Mutations in Plasma Circulating DNA From Patients With Metastatic Colorectal C NCT02751177 | Institut de Cancérologie de Lorraine | N/A |
| Completed | Development of an IDEAL Framework to Standardise Cytoreductive Surgery for Colorectal Peritoneal Metastases NCT03733184 | University of Manchester | — |
| Completed | Zinc Supplement in Regorafenib Treated mCRC Patient NCT03898102 | Chang Gung Memorial Hospital | Phase 2 |
| Unknown | Intraperitoneal and System Chemotherapy Versus XELOX as First-line Chemotherapy for mCRC NCT03792269 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Phase 2 |
| Terminated | Rechallenge of Cetuximab Combined With Irinotecan as Third-line Chemotherapy in Patients With Metastatic Color NCT02316496 | GERCOR - Multidisciplinary Oncology Cooperative Group | Phase 2 |
| Unknown | Effectiveness Study of Resection of Primary Tumor in Stage IV Colorectal Cancer Patients NCT02149784 | Sun Yat-sen University | Phase 3 |
| Completed | Masitinib in Combination With FOLFIRI in Third or Fourth Line of Treatment of Patients With Metastatic Colorec NCT03556956 | AB Science | Phase 2 / Phase 3 |
| Completed | To Assess the Safety of Continuous IV Administration of Plerixafor in Patients With Advanced Pancreatic, Ovari NCT02179970 | CCTU- Cancer Theme | Phase 1 |
| Unknown | Possible Association of Intestinal Helminths and Protozoa With Colorectal Cancer Pathogenesis NCT03173001 | Research Institute of Epidemiology, Microbiology and Infectious Diseases, Uzbekistan | — |
| Completed | Safety and Efficacy Study of Famitinib in Patients With Advanced Colorectal Adenocarcinoma（FACT） NCT02390947 | Jiangsu HengRui Medicine Co., Ltd. | Phase 3 |
| Completed | The Oncopanel Pilot (TOP) Study NCT02171286 | British Columbia Cancer Agency | — |
| Completed | Study to Evaluate Real-world Pharmacoeconomics and Resistance Mechanisms of Panitumumab in Metastatic Colorect NCT02135757 | PeriPharm | — |
| Completed | Pilot Study to Assess the Safety and Pharmacokinetics of 70-150μm Drug Eluting Beads Loaded With Irinotecan (D NCT02350400 | Singapore General Hospital | Phase 1 |
| Completed | Study to Evaluate Real-world Pharmacoeconomics of Panitumumab in Metastatic Colorectal Cancer Patients NCT02139215 | PeriPharm | — |
| Withdrawn | Capecitabine Plus Aflibercept as Maintenance Therapy Following Capecitabine Plus Oxaliplatin Plus Aflibercept NCT02085005 | Sanofi | Phase 2 |
| Terminated | Study of Aflibercept as Maintenance Therapy Following Induction With Aflibercept in Combination With XELOX, as NCT01955629 | Sanofi | Phase 1 / Phase 2 |
| Completed | The Jules Bordet Institute Molecular Profiling Program Feasibility Trial NCT01932489 | Jules Bordet Institute | N/A |
| Unknown | Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer NCT01910610 | GERCOR - Multidisciplinary Oncology Cooperative Group | Phase 3 |
| Unknown | Efficacy and Safety of Raltitrexed-based Transarterial Chemoembolisation(TACE)for Colorectal Cancer Liver Meta NCT01959061 | Nanjing Chia-tai Tianqing Pharmaceutical | Phase 4 |
| Completed | A Study of Aflibercept in Combination With FOLFIRI in Patients With Second-Line Metastatic Colorectal Cancer i NCT01882868 | Sanofi | Phase 2 |
| Terminated | Efficacy of FOLFOX Alone, FOLFOX Plus Bevacizumab and FOLFOX Plus Panitumumab in Patients With Resectable Live NCT01508000 | European Organisation for Research and Treatment of Cancer - EORTC | Phase 2 |
| Completed | FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal C NCT01721954 | Sirtex Medical | Phase 3 |
| Terminated | Colorectal Cancer (CRC) Cetuximab Elderly Frail NCT01522612 | European Organisation for Research and Treatment of Cancer - EORTC | Phase 2 |
| Unknown | RAS Switch in Patients With Metastatic RAS Native Colorectal Tumors Treated With 1st Line FOLFIRI-Cetuximab NCT01943786 | Sofia Perea, Director Clinical Trials Unit. | — |
| Completed | Monocentric Prospective Pilot Study Evaluating the Value of Indocyanine Green (ICG, Indocyanine Green) During NCT01982227 | Centre Hospitalier Universitaire de Saint Etienne | — |
| Completed | Study of Tivantinib (ARQ 197) Plus Cetuximab in EGFR Inhibitor-Resistant MET High Subjects NCT01892527 | Armando Santoro, MD | Phase 2 |
| Completed | Chemotherapy Alone Versus Chemotherapy Plus Targeted Therapy as Adjuvant Therapy for Initially Unresectable Co NCT06027775 | Fudan University | — |
| Withdrawn | Efficacy of FOLFOX Versus FOLFOX Plus Aflibercept in K-ras Mutant Patients With Resectable Liver Metastases NCT01646554 | European Organisation for Research and Treatment of Cancer - EORTC | Phase 2 / Phase 3 |
| Terminated | Maintenance Metronomic Chemotherapy for Metastatic Colorectal Carcinoma NCT01668680 | HaEmek Medical Center, Israel | Phase 2 |
| Completed | Colorectal Cancer Metastatic NCT01670721 | Sanofi | Phase 3 |
| Completed | A Study of Aflibercept Versus Placebo With FOLFIRI in Patients With Metastatic Colorectal Cancer Previously Tr NCT01661270 | Sanofi | Phase 3 |
| Completed | Gemcitabine in Combination With Pemetrexed Long Term Infusion in the Treatment of Pretreated Metastatic Colore NCT01909830 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Phase 2 |
| Completed | Influence of BRAF and PIK3K Status on the Efficacy of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFIRI) Plus Bev NCT01640444 | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | Phase 2 |
| Completed | Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treat NCT01571284 | Sanofi | Phase 3 |
| Completed | A Study of Famitinib in Patients With Advanced Colorectal Cancer NCT01762293 | Jiangsu HengRui Medicine Co., Ltd. | Phase 2 |
| Completed | Efficacy Evaluation of TheraSphere Following Failed First Line Chemotherapy in Metastatic Colorectal Cancer NCT01483027 | Boston Scientific Corporation | N/A |
| Completed | Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer NCT01471353 | University of Florida | Phase 2 |
| Terminated | Study Comparing Optimized 5-FU Dosing and Standard Dosing in Metastatic Colorectal Cancer Patients Treated Wit NCT01468623 | Myriad Genetic Laboratories, Inc. | Phase 4 |
| Completed | Does Acne Rash During Adolescence Predict Skin Reaction to Cetuximab NCT01382407 | Rambam Health Care Campus | — |
| Completed | Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer NCT01298570 | UNC Lineberger Comprehensive Cancer Center | Phase 2 |
| Unknown | FOLFIRI in Combination With Cetuximab in the First-line Treatment of Metastatic Colorectal Cancer Including a NCT01315990 | Dr. Carl Schimanski | Phase 4 |
| Terminated | Pre-emptive Cycline Treatment on Cetuximab Induced Skin Toxicity in Colorectal Cancer NCT01317433 | Institut Cancerologie de l'Ouest | N/A |
| Unknown | Cap+Bev vs Cap+Iri+Bev 1st-line Therapy in mCRC NCT01249638 | Ludwig-Maximilians - University of Munich | Phase 3 |
| Terminated | Combined Anticancer Treatment of Advanced Colon Cancer NCT01540344 | University of Regensburg | Phase 2 |
| Completed | Open-Label Phase 2 Efficacy Trial of Cancer Macrobeads in Patients With Treatment-Resistant Pancreatic/Colorec NCT01053013 | The Rogosin Institute | Phase 2 |
| Completed | First-line FOLFOXIRI In Combination With Bevacizumab For Metastatic Colorectal Cancer NCT01163396 | Gruppo Oncologico del Nord-Ovest | Phase 2 |
| Unknown | Maintenance Treatment Versus Observation After Induction in Advanced Colorectal Carcinoma NCT00442637 | Dutch Colorectal Cancer Group | Phase 3 |
| Completed | PET Evaluation of Response After 1 Course of Chemotherapy as Predictor of Treatment Outcome. NCT00741481 | Jules Bordet Institute | — |
| Completed | Chemotherapy and Tumor Clearance in Hepatic Resections for Colorectal Liver Metastases. NCT05273489 | Hospital Maciel | — |
| Approved For Marketing | Expanded Access Study of TAS-102 in Patients With Metastatic Colorectal Cancer NCT02286492 | Taiho Oncology, Inc. | — |